HK Stock Market Move | ASCLETIS-B (01672) rose by more than 7%. It is expected to submit an IND for ASC36 oral tablets for treating obesity to the FDA in the second quarter.

ASCLETIS-B (01672) rose by over 7%, with a cumulative increase of over 30% within the month. As of the time of writing, it rose by 6.42% to 18.24 Hong Kong dollars, with a trading volume of 17.9992 million Hong Kong dollars. On the news front, on February 11th, ASCLETIS-B announced that its board of directors has selected its first oral glucagon-like peptide-1 receptor agonist peptide ASC36 oral tablet for clinical development. Geeli is expected to submit a new drug clinical trial application (IND) for ASC36 oral tablets for the treatment of obesity to the US Food and Drug Administration (FDA) in the second quarter of 2026. Compared with a recently FDA-approved GLP-1R agonist peptide, due to its potential for better oral bioavailability and efficacy, it is expected that the dosing of ASC36 oral tablets will be lower. The superior weight-loss effect per milligram of ASC36 peptide may also lead to lower costs in large-scale production. ASC36 is a glucagon-like peptide-1 receptor agonist peptide developed independently by Geeli using its AI-assisted Structure-Based Drug Discovery (AISBDD) technology. The ASC36 oral tablet formulation was developed and optimized by Geeli using its proprietary POTENT technology, which is used to achieve oral peptide delivery.